Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-29821
Senti, G; Graf, N; Haug, Susanne; Rüedi, N; von Moos, S; Sonderegger, T; Johansen, P; Kündig, T M (2009). Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 124(5):997-1002.
- Registered users only
BACKGROUND: Subcutaneous allergen-specific immunotherapy is an effective treatment of IgE-mediated allergies, but it requires repeated allergen injections with a risk of systemic allergic reactions. Transcutaneous immunotherapy may improve patient compliance and safety. OBJECTIVE: To assess the safety and efficacy of epicutaneous allergen immunotherapy. METHODS: This monocentric, placebo-controlled, double-blind trial was conducted from March 2006 to December 2007 at the University Hospital Zurich. Thirty-seven adult patients with positive skin prick and nasal provocation tests to grass pollen were randomized to receive patches containing either allergen (n = 21) or placebo (n = 16). Treatment took place before and during the pollen season 2006, and follow-up visits took place before (n = 26) and after the pollen season 2007 (n = 30). The primary outcome measures were nasal provocation tests. RESULTS: Allergen-treated patients showed significantly decreased scores in nasal provocation tests in the first (P < .001) and second year (P = .003) after treatment. In contrast, placebo-treated patients had decreased scores in the first treatment year, 2006 (P = .03), but the effect diminished in the second year (P = .53). Although improvement of nasal provocation test scores was not significantly better in the verum versus placebo group, the overall treatment success was rated significantly higher by the allergen-treated group than by the placebo group (2006, P = .02; 2007, P = .005). No severe adverse events were observed. Occurrence of eczema after allergen patch applications proved stimulation of specific T-cell responses, but was noted as an adverse effect of the treatment. CONCLUSION: Epicutaneous allergen immunotherapy is a promising strategy to treat allergies and merits further investigation.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
04 Faculty of Medicine > Center for Medical Research
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Deposited On:||09 Feb 2010 08:15|
|Last Modified:||04 Sep 2014 10:05|
|Citations:||Web of Science®. Times Cited: 60|
Scopus®. Citation Count: 72
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page